The reimbursement of emerging durable/potentially curative cell and gene therapies is likely to be a challenge for the US healthcare market. Considering the pricing of cell- and gene-based therapies approved thus far, the acute cost of the numerous pipeline products likely to launch soon may be substantial for payers. This cost, in addition to the lack of long-term clinical durability data, could mean that payers will be reluctant to fund these types of therapies, which could have serious negative consequences for patients.
Share the research